Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Dyne Therapeutics (NASDAQ: DYN) and has maintained a price target of $47 for the stock. This indicates a positive outlook for the company's performance in the market.